Abbreviations
=============

CNA

:   copy number alteration

CT antigen genes

:   cancer-testis or cancer-germline antigen genes

DAC

:   decitabine, 5-Aza-2′-deoxycytidine

DFS

:   disease-free survival

DNMT

:   DNA methyltransferase

EOC

:   epithelial ovarian cancer

FTE

:   normal fallopian tube epithelia

HGSOC

:   high-grade serous ovarian cancer

IHC

:   immunohistochemistry

NO

:   bulk normal ovary

OS

:   overall survival

OSE

:   normal ovary surface epithelia

RLM-RACE

:   5′ RNA ligase-mediated rapid amplification of cDNA ends

RNA-seq

:   RNA sequencing

TCGA

:   The Cancer Genome Atlas

TMA

:   tissue microarray

TSS

:   transcription start site

Introduction {#s0001}
============

Ovarian cancer is the seventh most common cancer among women worldwide, and the fifth leading cause of cancer death in US women, with an estimated 14,180 deaths in 2015.[@cit0001] Ninety percent of ovarian cancer is epithelial in origin (EOC).[@cit0003] The 5 year survival rate for women diagnosed with localized EOC exceeds 90%; however, more than 60% of cases are diagnosed with advanced disease, and the 5 year survival rate for these patients is less than 30%.[@cit0002] Current standard of care therapy for EOC is cytoreductive surgery followed by combination platinum-taxane chemotherapy.[@cit0004] Disease recurrence occurs in greater than 70% of patients initially responsive to this therapy, and there is no durable cure for recurrent ovarian cancer.[@cit0005] Achieving an improved understanding of the molecular pathogenesis of EOC is required to develop new biomarkers for early detection as well as novel therapeutic approaches.

Cancer testis (CT) antigen genes, also known as cancer germline genes, are normally expressed only in germ cells, but are aberrantly expressed in a wide range of human cancers.[@cit0006] CT genes frequently encode antigens that can elicit spontaneous immune responses in cancer patients, and this, coupled with their highly restricted expression in normal somatic tissues, makes them ideal immunotherapy targets.[@cit0006] CT antigen genes are often regulated at the transcriptional level by promoter DNA methylation and other epigenetic mechanisms, including global DNA methylation status, histone acetylation, and nucleosome occupancy.[@cit0007]

CT45 is a recently discovered sub-family of CT genes composed of 6 highly related paralogs: *CT45A1* (GenBank ID: 541466), *CT45A2* (GenBank ID: 728911), *CT45A3* (GenBank ID: 441519), *CT45A4* (GenBank ID: 441520), *CT45A5* (GenBank ID: 441521), and *CT45A6* (GenBank ID: 541465).[@cit0014] CT45 genes are located in a tandem arrangement at chromosome Xq26.3 and encode highly similar mRNAs and proteins, with 98% conservation at the amino acid level, suggesting evolutionary emergence via gene duplications. CT45 is localized in the nucleus, and 2 nuclear localization signals have been defined.[@cit0015] In normal tissues, *CT45* mRNA expression was detected with a strong signal in testis and weak signal in lung, heart, spinal cord, and brain,[@cit0014] while the CT45 protein was detected only in primary spermatocytes and gonocytes.[@cit0015] Unlike its highly restricted expression in normal tissues, CT45 is expressed widely in human cancer. In some tumor types, CT45 is expressed in a low proportion of cases, e.g., myeloma (16%),[@cit0019] lung (13%),[@cit0017] colon (11%), [@cit0016] and breast (5--10%),[@cit0017] while, in other tumor types, CT45 exhibits widespread expression, e.g., seminoma (\>90%),[@cit0016] Hodgkin\'s lymphoma (\>50%) [@cit0016], EOC (37%),[@cit0017] and diffuse large B-cell lymphoma (22%).[@cit0022] In addition to its mere expression in cancer, CT45 expression has also been correlated with more aggressive disease. In Hodgkin\'s lymphoma, CT45 expression correlated with more aggressive histological subtypes, disease symptoms, and advanced stages.[@cit0021] In multiple myeloma, CT45 expression correlated with poor survival.[@cit0019] In breast cancer, CT45 expression correlated with high grade, and ER negative, HER2 negative status, suggesting it could be used as a potential immunotherapeutic target in triple negative breast cancer.[@cit0018]

Widespread expression in specific human cancers coupled with increased expression in more aggressive disease states have led to speculation that CT45 may play direct roles in oncogenesis. In support of this hypothesis, 2 recent studies of CT45 provide initial evidence for an oncogenic role for CT45 proteins.[@cit0023] Koop et al. demonstrated that CT45 knockdown in Hodgkin\'s lymphoma and multiple myeloma cell lines reduced cell adhesion, migration, and invasion.[@cit0023] Shang et al. similarly found that CT45A1 overexpression increased migration and invasion, promoted epithelial to mesenchymal transition (EMT), and increased xenograft growth and metastasis, using the MCF7 breast cancer cell line as a model.[@cit0024] In both studies, CT45 was not observed to play a role in cell growth or cell cycle progression, but only in phenotypic characteristics related to metastatic tumor growth.

The mechanism leading to CT45 expression in cancer has not been well defined. One study reported that treatment with decitabine, a DNA hypomethylating agent, induced CT45 expression in HeLa cells and stimulated peripheral blood lymphocytes.[@cit0016] However, decitabine has both on-target and off-target effects,[@cit0025] and the promoter methylation status of *CT45* genes has not been directly determined, either in samples expressing these genes or in those in which it is silent. Furthermore, demonstration that DNA methylation directly impacts CT45 promoter activity has not been provided. In the current study, we conducted a thorough investigation of the expression of CT45 genes in EOC and normal control tissues, and the role of DNA methylation (both promoter-specific and global methylation) in its regulation. In addition, we analyzed the relationship between CT45 expression, DNA methylation, and EOC disease progression and patient survival.

Results {#s0002}
=======

*CT45* mRNA expression in EOC {#s0002-0001}
-----------------------------

Due to the high sequence conservation of the 6 *CT45* paralogs, we were unable to accurately measure individual *CT45* gene expression by RT-PCR (data not shown). Therefore, we used *pan-CT45* amplification primers to measure *CT45* expression by reverse transcriptase quantitative PCR (RT-qPCR) (**Table S1**). We first determined *CT45* expression in a large set (\>100) of EOC samples as well as bulk normal ovary (NO) samples as controls (EOC clinical information shown in **Table S2**). As shown in [**Fig. 1A**](#f0001){ref-type="fig"}, *CT45* was not expressed in NO but was activated in a significant proportion of EOC (25%). The majority of EOC, including those in our sample collection, have serous histology (**Table S2**). We observed that serous, but not non-serous EOC, expressed significantly higher *CT45* as compared to NO ([**Fig. 1B**](#f0001){ref-type="fig"}; **Fig. S1**). We examined the influence of disease stage and grade on *CT45* expression and found that *CT45* is activated only in late stage and high-grade disease ([**Figs. 1C-D**](#f0001){ref-type="fig"}). In agreement, CT45 protein levels, as determined by immunohistochemistry (IHC) staining of EOC tissue microarrays (TMA),[@cit0017] indicated that CT45 protein expression was increased in late stage, high-grade disease (**Table S3**). Increased *CT45* expression correlated with reduced overall survival (OS) in EOC ([**Fig. 1E**](#f0001){ref-type="fig"}). A similar trend was observed for disease-free survival (DFS) but the difference was not statistically significant, likely due to the small set number of patients available for this analysis ([**Fig. 1F**](#f0001){ref-type="fig"}). Figure 1.*CT45* mRNA expression in EOC and its relation to clinicopathology. **(A-D)**. *CT45* mRNA expression relative to *18s rRNA* expression is shown for: **(A)** Bulk normal ovary (NO) and EOC, **(B)** EOC separated into non-serous and serous histotypes, **(C)** EOC separated by disease stage, and **(D)** EOC separated by pathological grade. Gene expression was determined by RT-qPCR. The two-tailed Mann-Whitney test p-value is indicated (\*: *P*\<0.05). For A-B, the proportion of EOC and serous samples with elevated *CT45* mRNA expression, respectively, is indicated. **(E)** Overall survival (OS) and **(F)** disease-free survival (DFS) of EOC patients as a function of *CT45* expression. Patients were dichotomized at the median *CT45* mRNA expression value. Logrank *P*-values are indicated.

*CT45* copy number alterations do not correlate with *CT45* mRNA expression in EOC {#s0002-0002}
----------------------------------------------------------------------------------

Copy number alterations are very common in EOC, and have the capacity to deregulate gene expression.[@cit0026] As mentioned earlier, *CT45* genes are located in a tight arrangement on Xq26.3,[@cit0014] and coordinated chromosomal gains or amplifications at this region could potentially account for *CT45* activation in EOC. To investigate this possibility, we retrieved The Cancer Genome Atlas (TCGA) data, including RNA sequencing (RNA-seq) and copy number alteration (CNA) data for high-grade serous ovarian cancer (HGSOC), the most common EOC subtype.[@cit0026] Of 265 tumors with RNA-seq data (microarray data was sparse for *CT45*), 37 (14%) showed activation of at least one *CT45* gene ([**Fig. 2A**](#f0002){ref-type="fig"}). This was a lower frequency than we observed by RT-qPCR in our data set, potentially due to the increased sensitivity of RT-qPCR or to our measurement of *Pan-CT45* expression ([**Figs. 1A-B**](#f0001){ref-type="fig"}). As expected, *CT45* family members showed overlapping expression ([**Fig. 2A**](#f0002){ref-type="fig"}). Among 579 tumors with CNA data, 70% of cases showed a *CT45* alteration, and there was complete overlap among the 6 *CT45* genes (**Fig. S2**). The CNAs included roughly equivalent amounts of gains and deletions ([**Fig. 2B**](#f0002){ref-type="fig"}). Notably, *CT45* expression did not correlate with copy number status ([**Fig. 2C**](#f0002){ref-type="fig"}; representative data shown for *CT45A1*). Thus, alternative mechanisms are likely to account for the expression pattern of *CT45* observed in EOC. Figure 2.*CT45* mRNA expression and copy number alterations (CNA) in EOC. Data were obtained from the TCGA and analyzed using cBioPortal as described in *Materials and Methods*. **(A)** *CT45* family mRNA expression in 265 HGSOC EOC tumors, as determined by RNA-seq. Upregulation, downregulation, and the percentage of cases altered are indicated. **(B)** Synopsis of *CT45* CNA in 579 HGSOC samples. **(C)** *CT45A1* expression plotted as a function of *CT45A1* copy number status. Mann-Whitney t-tests indicated no significant differences in any pairwise group analysis; similar results were obtained for other *CT45* family members (data not shown).

5′ end *CT45* transcript mapping in normal testis and EOC {#s0002-0003}
---------------------------------------------------------

The 5′ end and promoter regions of *CT45* genes do not contain classical CpG islands[@cit0027]; however, the predicted *CT45* transcriptional start sites (TSS) are flanked by several CpG dinucleotides, suggesting that DNA methylation could play a transcriptional regulatory role for these genes (**Fig. S3**). As a prelude to understanding the potential role of DNA methylation in *CT45* regulation, we first mapped the TSS of *CT45* genes. Specifically, we used 5′ RNA ligase-mediated rapid amplification of cDNA ends (RLM-RACE) [@cit0028] to determine the TSS in both normal human testis and an admixture of 2 EOC samples with high *CT45* expression. RLM-RACE primer sequences are shown in **Table S1**. We observed several alternative TSSs for *CT45*, all but one of which was downstream of the NCBI-predicted TSS (**Fig. S3**). The variable nature of the *CT45* TSS is consistent with the absence of a TATA box in its promoter.[@cit0030] The TSS detected in normal testis and EOC overlapped, suggesting relative conservation in normal tissues and cancer. Unexpectedly, RLM-RACE additionally detected fusion sequences in EOC, in which the *CT45* sequence contained an insert derived from a nearby locus on chromosome X (data not shown). A previous study reported MLL-*CT45A2* fusion transcripts in pediatric biphenotypic acute leukemia.[@cit0031] These observations suggest that the *CT45* locus could be a hotspot for cancer-related translocations.

*CT45* promoter hypomethylation in EOC {#s0002-0004}
--------------------------------------

Based on the NCBI-predicted TSS for *CT45*, as well as that determined by RLM-RACE, we designed bisulfite clonal sequencing primers covering 2 relevant regions of the *CT45* promoter region (**Table S1**; [**Fig. 3A**](#f0003){ref-type="fig"}). We analyzed 5 samples by bisulfite sequencing, including one NO, 2 EOC with high *CT45* expression, and 2 EOC with low *CT45* expression. We observed highest *CT45* methylation of both regions in NO, some hypomethylation in the *CT45* negative EOC samples, and the highest degree of hypomethylation in the *CT45* positive EOC samples ([**Figs. 3A-B**](#f0003){ref-type="fig"}), suggesting an indirect association between *CT45* expression and promoter methylation. To confirm the relationship between promoter hypomethylation and *CT45* expression in EOC, we designed high-throughput bisulfite pyrosequencing assays to interrogate 4 CpG sites showing correlation between hypomethylation and expression in bisulfite sequencing (**Table S1**; [**Fig. 3A**](#f0003){ref-type="fig"}). In these experiments, in addition to using bulk normal ovary (NO) as a control, we also measured *CT45* methylation in primary ovarian surface epithelia (OSE) and fallopian tube epithelia (FTE), 2 presumed tissues of origin of EOC. As shown in [**Figs. 4A-B**](#f0004){ref-type="fig"}, OSE and FTE had high *CT45* promoter methylation, NO also had high levels of *CT45* methylation (however a small degree of hypomethylation was apparent in Region 2), and EOC samples showed heterogeneous methylation, with roughly half (Region 1) or 2-thirds (Region 2) of the samples showing hypomethylation as compared to control tissues. Reduced methylation at Region 2 in bulk NO, as compared to OSE and FTE, may be due to the presence of other cell types, including germ cells, in this tissue ([**Fig. 4B**](#f0004){ref-type="fig"}). Methylation at the 2 different *CT45* promoter regions was highly correlated in EOC ([**Fig. 4C**](#f0004){ref-type="fig"}). Figure 3.Sodium bisulfite clonal sequencing of the *CT45* promoter. **(A) Upper**: diagram of the *CT45* promoter region, indicating CpG sites (black hash marks), predicted or mapped TSS (right broken arrows, see **Fig. S3**), regions analyzed by pyrosequencing (rectangles; see subsequent figures), and a CpG site differentially present in *CT45* family members (inverted triangle). **Lower**: bisulfite clonal sequencing results for 2 regions of the *CT45* promoter. Filled and open circles indicate methylated and unmethylated CpG sites, and each row represents one sequenced allele. Data are shown for a NO sample (NO1), 2 EOC samples with low *CT45* expression (EOC99 and EOC83), and 2 EOC samples with high *CT45* expression (EOC100 and EOC89). **(B)** Graphical summary of the data presented in **A**. Figure 4.Sodium bisulfite pyrosequencing of the *CT45* promoter. The methylation status of 2 different regions of the *CT45* promoter (indicated by rectangles in [**Fig. 3A**](#f0003){ref-type="fig"}), were analyzed by sodium bisulfite pyrosequencing in an expanded set of clinical samples including: OSE: normal ovary surface epithelia, FTE: normal fallopian tube epithelia, NO: normal bulk ovary tissue, and EOC: epithelial ovarian cancer. **(A)** Pyrosequencing data for Region 1. **(B)** Pyrosequencing data for Region 2. The proportion of EOC samples with *CT45* promoter hypomethylation as compared to OSE and FTE are indicated. The two-tailed Mann-Whitney test *P*-value is indicated (\*: *P* \<0.05; \*\*\*: *P*\<0.001; \*\*\*\*: *P*\<0.0001). **(C)** Correlation between *CT45* Region 1 and Region 2 methylation in EOC samples. Spearman test results are shown.

*CT45* promoter hypomethylation correlates with CT45 mRNA and protein expression in EOC {#s0002-0005}
---------------------------------------------------------------------------------------

To determine if *CT45* hypomethylation correlates with CT45 expression, we first compared *CT45* methylation as determined by pyrosequencing to *CT45* mRNA expression as determined by RT-qPCR. For both pyrosequencing regions, we observed a significant inverse correlation with *CT45* mRNA expression in EOC ([**Figs. 5A-B**](#f0005){ref-type="fig"}). Second, by comparison to a previously published TMA IHC data set,[@cit0017] we found that *CT45* promoter methylation was significantly lower in EOC samples positive for CT45 protein expression as compared to those negative for CT45 ([**Figs. 5C-D**](#f0005){ref-type="fig"}). Representative examples of negative, weak, and strong CT45 IHC-staining HGSOC tumors are shown in [**Fig. 5E**](#f0005){ref-type="fig"}. The staining pattern observed was nuclear ([**Fig. 5E**](#f0005){ref-type="fig"}). Figure 5.CT45 expression and promoter methylation in EOC. **(A-B)** *CT45* mRNA expression was measured by RT-qPCR and was normalized to *18s rRNA* expression. *CT45* Region 1 **(A)** and Region 2 **(B)** methylation were measured by pyrosequencing. Samples with undetectable *CT45* mRNA are plotted on the x-axis. Spearman test results are shown. **(C-D)** CT45 protein expression was measured by IHC using an EOC TMA as described in *Materials and Methods*. EOC samples with weak (W), moderate (M), or strong (S) CT45 IHC signal (see **Table S1**) were classified as CT45-positive, while samples with no CT45 IHC signal were classified as CT45-negative. *CT45* Region 1 **(C)** and Region 2 **(D)** methylation were measured by pyrosequencing. The two-tailed Mann-Whitney test p-value is indicated (\*: *P* \< 0.05). **(E)** CT45 IHC TMA staining of HGSOC samples, showing representative images of negative, weak, and strong staining. Upper and lower rows show low and high magnification images of 0.6 mm TMA cores, respectively.

*CT45* promoter methylation is decreased during disease progression and is associated with reduced survival in EOC patients {#s0002-0006}
---------------------------------------------------------------------------------------------------------------------------

We next compared *CT45* promoter methylation levels, at both pyrosequencing regions, with clinical stage and histological grade in EOC. While both pyrosequencing regions showed hypomethylation in advanced stage disease, the trend in *CT45* promoter Region 1 also met statistical significance ([**Figs. 6A-B**](#f0006){ref-type="fig"}). Similar results were observed for tumor grade ([**Figs. 6C-D**](#f0006){ref-type="fig"}). Thus, similar to *CT45* expression ([**Figs. 1B-C**](#f0001){ref-type="fig"}), *CT45* promoter hypomethylation correlates with disease progression. With regards to survival, OS was reduced in patients with *CT45* promoter hypomethylation, and this difference was highly significant for Region 1 ([**Figs. 7A-B**](#f0007){ref-type="fig"}). Although fewer patients were available for DFS analysis, we observed a trend toward reduced DFS with hypomethylation of *CT45* Region 1, and a statistically significant difference for *CT45* Region 2 ([**Figs. 7C-D**](#f0007){ref-type="fig"}). Figure 6.*CT45* promoter methylation and EOC disease progression. **(A-B)** *CT45* promoter Region 1 **(A)** and Region 2 **(B)** methylation was determined by pyrosequencing and is plotted as a function of EOC clinical stage. **(C-D)** *CT45* promoter Region 1 **(C)** and Region 2 **(D)** methylation was determined by pyrosequencing and is plotted as a function of EOC histological grade. The two-tailed Mann-Whitney test *p*-value is indicated (\*: *P* \< 0.05). Figure 7.*CT45* promoter methylation and EOC patient survival. **(A-B)** *CT45* promoter Region 1 **(A)** and Region 2 **(B)** methylation was determined by pyrosequencing. Patients were dichotomized at the median methylation value and OS was compared using Kaplan Meier analysis and Logrank test. **(C-D)** Same as A-B except DFS was compared.

*CT45* hypomethylation and expression are associated with *LINE-1* hypomethylation, and *CT45* is co-expressed with other CT antigen genes, in EOC {#s0002-0007}
--------------------------------------------------------------------------------------------------------------------------------------------------

Prior data from the study of other CT antigen genes indicates connections between global loss of DNA methylation in cancer, promoter demethylation, and gene expression.[@cit0010] To address this critical question in the context of *CT45* in EOC, we measured *LINE-1* methylation as a surrogate for global methylation status,[@cit0032] and performed correlation analysis with *CT45* promoter methylation as determined by pyrosequencing. As shown in [**Figs. 8A-B**](#f0008){ref-type="fig"}, there was significant direct correlation between *CT45* promoter methylation and *LINE-1* methylation in EOC. Consistently, there was significant indirect correlation between *CT45* expression and *LINE-1* methylation ([**Fig. 8C**](#f0008){ref-type="fig"}). These data suggest that transcriptional regulation of *CT45* genes in EOC may in part reflect the global DNA methylation status of these tumors. If true, we would expect *CT45* expression to correlate with the expression of other CT antigen genes in EOC. Consistent with this idea, analysis of *Oncomine* datasets confirmed that *CT45A3* is co-expressed with other CT antigen genes in EOC, including several known to be regulated by DNA methylation, including *MAGE, GAGE*, and *XAGE* genes ([**Fig. 8D**](#f0008){ref-type="fig"}). Figure 8.*CT45* methylation and expression, *LINE-1* methylation, and CT gene co-expression in EOC. **(A-B)** *CT45* promoter Region 1 **(A)** and Region 2 **(B)** methylation as compared to *LINE-1* methylation in EOC. All methylation data were determined by pyrosequencing. **(C)** *CT45* mRNA expression as compared to *LINE-1* methylation in EOC. *CT45* mRNA expression was measured by RT-qPCR and was normalized to *18s rRNA* expression. Samples with undetectable *CT45* mRNA levels were plotted on the x-axis. **(D)** *Oncomine* analysis of the genes most closely correlated with *CT45A3* in the Bittner ovarian cancer dataset (see *Materials and Methods* for details). Correlation coefficient and gene name are shown at left. All genes besides *C18orf2* are known, or likely (*GTSF1*), CT genes (see CTDatabase, <http://www.cta.lncc.br/>).

Decitabine treatment induces CT45 mRNA and protein expression in EOC cell lines {#s0002-0008}
-------------------------------------------------------------------------------

The primary tumor data presented above establishes a correlation between *CT45* promoter hypomethylation and CT45 expression, but does not demonstrate causation. To establish a mechanistic connection, we first treated EOC cell lines with varying levels of baseline CT45 expression with the DNA methyltransferase (DNMT) inhibitor decitabine (DAC), a cytosine analog that specifically inhibits DNA methylation by covalently trapping DNMTs to DNA.[@cit0033] Following DAC treatment, the *CT45* promoter was hypomethylated in all treated cell lines ([**Fig. 9A**](#f0009){ref-type="fig"}). Notably, *CT45* expression was robustly induced in each of the low expressing cell lines (i.e., IOSE121, OVCAR3, SNU119), with less or no induction in 2 lines with higher basal *CT45* expression (A2780, OVSAHO) ([**Fig. 9A**](#f0009){ref-type="fig"}). Importantly, CT45 protein was also induced, albeit to varying levels, in EOC cell lines treated with DAC ([**Fig. 9B**](#f0009){ref-type="fig"}). Figure 9.Decitabine-mediated induction of CT45 expression in EOC cells. The indicated cell lines were treated with 1µM decitabine (DAC) for 5 days as described in *Materials and Methods*. **(A)** *CT45* mRNA expression and *CT45* promoter methylation after vehicle (PBS) or DAC treatment. *CT45* mRNA expression was determined by RT-qPCR and *CT45* promoter methylation was determined by pyrosequencing (average of Region 1 + Region 2 methylation). Data represent mean +/-- SD. The two-tailed paired t-test p-value is indicated (\*:*P* \< 0.05; \*\*: *P* \< 0.01; \*\*\*\*: *P* \< 0.0001; NS: not significant). **(B)** Western blot analysis of CT45 protein expression after vehicle (PBS, --) or DAC (+) treatment. β-actin and FastGreen staining are shown as loading controls.

DNA methylation directly represses *CT45* promoter activity {#s0002-0009}
-----------------------------------------------------------

To determine whether the inhibitory action of DNA methylation on CT45 expression is direct or indirect, we used a promoter-luciferase reporter approach. We cloned 2 overlapping regions of the *CT45* promoter into the CpG-free vector pCpGL-basic,[@cit0034] which allowed specific methylation of *CT45* promoter inserts. A schematic of the *CT45A2* promoter (the gene chosen for analysis) along with the position of different methyltransferase acceptor sites is shown in [Figure 10A](#f0010){ref-type="fig"}. We tested the activity of both *CT45* promoter constructs, in the absence or presence of methylation, using 2 different EOC cell lines, OVCAR3 and A2780. The constructs were either mock-methylated or methylated with one of 3 different CpG methylases that targeted a different number of CpG sites in each construct ([**Fig. 10A**](#f0010){ref-type="fig"}). As shown in [Figs. 10B-C](#f0001){ref-type="fig"}, highly similar results were obtained in each EOC cell line, with repression of each promoter construct by DNA methylation. Interestingly, construct 2, but not construct 1, showed maximal repression with either *Hha*I or *Hpa*II methylation, despite the fact that less CpG sites are methylated by these enzymes as compared to *M.Sss*I ([Figs. 10B-C](#f0001){ref-type="fig"}). The *in vivo* relevance of this observation remains to be determined. Regardless, our data establish DNA methylation as a direct repressor of *CT45* promoter activity in EOC cells. Figure 10.Effect of DNA methylation on *CT45* promoter activity. **(A)** Diagram of the *CT45A2* promoter region and 2 constructs used for promoter activity assay. Black hash marks represent CpG sites. NCBI-predicted and RLM-RACE mapped TSS are indicated by the right broken arrows as in [**Fig. 3A**](#f0003){ref-type="fig"}. The two regions analyzed by pyrosequencing are indicated by black lines. The different methyltransferase acceptor sites are labeled in the legend. **(B-C)** Luciferase activity data for *CT45* promoter constructs in **(B)** OVCAR3 and **(C)** A2780 EOC cell lines. Constructs were either mock-methylated or methylated with *Hha*I, *Hpa*II, or *M.Sss*I prior to transfection as described in Materials and Methods. CT45 firefly luciferase/renilla luciferase (control) enzymatic activity data are shown. Data represent mean ± SD.

Discussion {#s0003}
==========

We examined the role of DNA methylation in the regulation of CT45 expression in EOC. *CT45* was expressed in ∼25% of EOC patient samples, and its expression was significantly increased in serous tumors, advanced stage, and high-grade lesions. Promoter hypomethylation of *CT45* genes was observed in \>50% of EOC samples, and this was exacerbated in advanced disease. Both *CT45* expression and promoter hypomethylation were associated with reduced OS and DFS, consistent with their alteration during disease progression, and suggesting potential utility as prognostic biomarkers for EOC.

We validated a link between DNA methylation alterations and CT45 expression in EOC both in clinical samples and EOC cell models. Importantly, *CT45* promoter hypomethylation was predictive of both *CT45* mRNA and CT45 protein expression. *CT45* hypomethylation also showed strong correlation with *LINE-1* hypomethylation, providing evidence that CT45 expression is linked to the global hypomethylation process that frequently impacts the cancer genome. While this link could be used to argue that CT45 (and more generally CT antigen) gene expression could be a passenger effect, the emerging oncogenic functions of CT antigen genes, including *CT45*, alternatively suggests that CT antigen gene expression is under positive selection in cancer.[@cit0023] In the case of CT45, recent studies in Hodgkin\'s disease and breast cancer have established its function in promoting cell migration and invasion, as well as tumor growth and metastasis *in vivo*.[@cit0023] The mechanism by which CT45 promotes these activities is not well understood, but may include regulation of the mRNA splicing machinery and/or transcriptional activation of critical pro-oncogenic genes such as TWIST.[@cit0023] Our future studies will include investigation of the oncogenic role of CT45 proteins in EOC.

Pharmacological inhibition of DNA methylation induced both CT45 mRNA and protein expression, and site-specific methylation of the *CT45* promoter significantly downregulated its activity. Further work is needed to define additional epigenetic and genetic mechanisms that regulate CT45 expression in EOC and other malignancies, and to compare these to the mechanisms regulating other CT antigen genes.[@cit0007] The more frequent occurrence of *CT45* hypomethylation than *CT45* expression in EOC additionally suggests that there may be a threshold of hypomethylation necessary to elicit *CT45* expression. This threshold level could be distinct in each tumor, depending upon the genomic and epigenomic context.

Treatment approaches for advanced EOC are challenged by the emergence of chemotherapy-resistant disease. The immune system may be uniquely suited to combat this problem, by virtue of its recognition of antigens specific to cancer tissues and due to its adaptive nature.[@cit0036] In this context, the CT antigen gene family is a potentially fruitful immunological target in EOC and other cancers due to their highly restricted pattern of expression and inherent immunogenicity.[@cit0006] Although spontaneous immune responses to CT45 in cancer patients have not been commonly observed, this does not exclude its potential utility as a cancer vaccination target.[@cit0017] In support of this idea, we observed a high titer antibody response to CT45 in a recent phase I clinical trial of doxil + decitabine + NY-ESO-1 vaccine in EOC.[@cit0037] In addition, a recent study of immune modulation using anti-CTLA4 antibody in melanoma patients demonstrated seroconversion to CT45.[@cit0038] However, our data suggest that CT45 based vaccination approaches might be most beneficial when occurring in the context of co-treatments that induce CT45 expression *in vivo*. Epigenetic modulators such as decitabine, SGI-110, or similar agents, may be well suited for utilization in this context.[@cit0039] Finally, we point out that the emerging oncogenic functions of CT45 suggest that therapeutics that directly target this protein family could also have utility in cancers that commonly express these proteins, including ER-negative breast cancer and HGSOC. A key advantage of such an approach would be a high level of specificity for tumor cells over normal cells.

Materials and Methods {#s0004}
=====================

Human tissues {#s0004-0001}
-------------

NO, OSE, FTE, and EOC samples were obtained under IRB-approved protocols at Roswell Park Cancer Institute as described previously.[@cit0032] Cell extracts of clinical samples were prepared as described previously.[@cit0042] EOC TMAs were constructed at Roswell Park Cancer Institute as described previously.[@cit0017] EOC clinical characteristics, and the molecular assay data for each sample, are shown in **Table S2**.

Human cell lines {#s0004-0002}
----------------

Human OSE cells immortalized with SV40 large T antigen (IOSE121), and EOC cell lines (A2780, OVCAR3), and their culturing methods were described previously.[@cit0042] SNU119 HGSOC cells [@cit0043] were obtained from the Korean Cell Line Bank and cultivated in RPMI1640 media supplemented with 10% FBS and 1% Pen-Strep. OVSAHO HGSOC cells [@cit0044] were obtained from the Japanese Collection of Research Bioresources, and cultivated in RPMI1640 media supplemented with 10% FBS and 1% Pen-Strep.

DNA, RNA, and protein extractions {#s0004-0003}
---------------------------------

Genomic DNA was isolated using the Puregene Tissue Kit (Qiagen), total RNA was purified using TRIzol® (Invitrogen), and total protein was extracted using RIPA buffer containing protease inhibitor cocktail (Sigma), according to standard methods.

Decitabine (DAC) treatment {#s0004-0004}
--------------------------

DAC was obtained from Sigma. Cells at ∼20% confluence were treated with 1 μM DAC (day 0), passaged at day 2, re-treated with 1 μM DAC at day 3, and harvested for cell extracts at day 5. PBS was used as the vehicle control. We observed slight to moderate toxicity in EOC cells using this regimen.

RT-qPCR {#s0004-0005}
-------

RNA was processed using the DNA-free kit (Ambion), and cDNA synthesis was performed using the iScript cDNA Synthesis Kit (BioRad). Gene expression was determined by qPCR using a BioRad CFX Connect system and the SYBR green method. Standard curves were prepared using a mixture of cDNA from EOC cell lines. Pan-*CT45* mRNA expression was normalized to *18s rRNA*. Primer sequences are provided in **Table S1**.

Western blotting {#s0004-0006}
----------------

Equal amounts of protein extracts (20 µg) were loaded per lane, separated using NuPAGE 4--12% Bis-Tris Gels (Invitrogen), and transferred to PVDF membranes (Roche) using the Trans-Blot SD Semi-Dry Transfer Cell (BioRad). Membranes were stained with FastGreen (Fisher) as a loading control. Western blotting was performed according to standard methods using human CT45-specific mouse polyclonal antibody ab169438 (1:100 dilution) (Abcam), and human β-Actin mouse monoclonal antibody sc-47778 (1:2000 dilution) (Santa Cruz).

CT45 protein expression on EOC TMAs {#s0004-0007}
-----------------------------------

EOC TMAs and CT45 protein staining by IHC was described previously.[@cit0017] Representative CT45 IHC staining of 0.6 mm TMA cores is shown in [**Fig. 5E**](#f0005){ref-type="fig"}.

RLM-RACE {#s0004-0008}
--------

The TSS of *CT45* were determined using the FirstChoice RLM-RACE Kit (Ambion). RNA samples included human normal testis (BioChain Institute), and total RNA from a mixture of 2 different EOC samples (EOC 89, EOC 100). Primer sequences are provided in **Table S1**. PCR products were analyzed as described previously.[@cit0042]

DNA methylation analyses {#s0004-0009}
------------------------

Bisulfite clonal sequencing and bisulfite pyrosequencing were used to determine the DNA methylation status of 5′ regions of *CT45* genes. Sodium bisulfite conversions utilized the EZ DNA Methylation Kit (Zymo Research). *CT45* bisulfite sequencing primers were designed using MethPrimer, and targeted 4 *CT45* family members: *CT45A2, CT45A3, CT45A4* and *CT45A5*. Bisulfite pyrosequencing assays were designed based on the *CT45A2* sequence, and assay 1 targets *CT45A2, A3, A4* and *A5*; assay 2 targets *CT45A2, A3, A4, A5* and *A6*. *LINE-1* methylation was determined using bisulfite pyrosequencing as described previously.[@cit0008] Primer sequences are provided in **Table S1**.

*CT45* co-expression with other CT antigen genes in EOC {#s0004-0010}
-------------------------------------------------------

*Oncomine* (Compendia Bioscience, Ann Arbor, MI) was used to analyze *CT45* expression in publically available human microarray data. Data are shown in [**Fig. 8D**](#f0008){ref-type="fig"} for the analysis of *CT45A3* co-expression in the Bittner human ovarian cancer data set, which used Affymetrix HG U133 Plus 2.0 arrays to profile 19,574 genes in 241 ovarian cancer samples of diverse histological origin (GEO accession number GSE2109).

*CT45* promoter activity {#s0004-0011}
------------------------

Two *CT45* promoter fragments (see [**Fig. 10A**](#f0010){ref-type="fig"}) were amplified using standard methods and cloned into pCR2.1 TOPO vector (Invitrogen). Inserts were then sub-cloned into the CpG-free vector, pCpGL-basic.[@cit0034] Purified plasmids were methylated *in vitro* with *M.Sss*I, *Hpa*II, *Hha*I, or no enzyme (mock), in the presence of S-adenosyl methionine (all enzymes and co-factor obtained from NEB). Methylation efficiency was confirmed by digesting the methylated constructs using endonucleases *Msp*I*, McrBC, Hha*I, and *Hpa*II (NEB) (data not shown). Cell lines were transiently transfected with 500 ng *CT45* firefly luciferase construct + 250 ng renilla luciferase control construct (pRL-TK) (Promega), using Lipofectamine 2000 (Invitrogen). Transfections were carried out in duplicate wells of 24 well plates. Cell extracts were harvested 24--48 hrs post-transfection, and firefly and renilla luciferase activity were measured using the Dual-Luciferase Reporter Assay System (Promega).

Survival analyses {#s0004-0012}
-----------------

OS was defined as the time between the date of diagnosis and death. Patients who were alive at the time of analysis were censored at the date of last follow-up. DFS was defined as the time between the date of surgery and disease recurrence. Patients who were alive and disease-free were censored at the date of last follow-up. For each molecular marker, samples were dichotomized at the median marker value, and the difference between the 2 groups was compared using Kaplan Meier analysis. The null hypothesis of no difference in the survival distributions was assessed using the Logrank test.

Analysis of *CT45* mRNA expression and CNA in TGCA data {#s0004-0013}
-------------------------------------------------------

TCGA genomic data for HGSOC (Ovarian Serous Cystadenocarcinoma-TCGA, Provisional) was retrieved and analyzed using cBioPortal (data upload March 9, 2015).[@cit0045] The following genomic profiles were analyzed: mutations, putative copy-number alterations from GISTIC using Onco Query Language (OQL), and mRNA expression data (RNA seq V2 RSEM). All parameters were set at default.
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